Most Americans would like the government to act, but a one-size-fits-all approach is unlikely to be the answer. Source: NYT > Business – Austin Frakt
Drugmaker Deals Are Near Record Pace in 2019, but Investors Don’t Love Them All
A rush of transactions is transforming the industry, as blockbuster medicines lose patent protection. The latest acquisition cost AbbVie 16 percent of its share price. Source: NYT > Business – Stephen Grocer